O	O	O	0	7	Vitamin	Vitamin	B-NP	NN	O	3	NMOD	O
O	O	O	8	9	E	E	I-NP	NN	O	3	NMOD	O
O	O	O	10	17	therapy	therapy	I-NP	NN	O	13	SUB	O
O	O	O	18	20	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	21	26	acute	acute	B-NP	JJ	O	6	NMOD	O
O	O	O	27	31	CCl4	CCl4	I-NP	NN	O	10	NMOD	O
O	O	O	31	32	-	-	O	HYPH	O	10	P	O
O	O	O	32	39	induced	induce	B-NP	VBN	O	10	NMOD	O
O	O	O	40	47	hepatic	hepatic	I-NP	JJ	O	10	NMOD	O
O	O	O	48	54	injury	injury	I-NP	NN	O	4	PMOD	O
O	O	O	55	57	in	in	B-PP	IN	O	3	NMOD	O
O	O	O	58	62	mice	mouse	B-NP	NNS	O	11	PMOD	O
O	O	O	63	65	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	66	76	associated	associate	I-VP	VBN	O	13	VC	O
O	O	O	77	81	with	with	B-PP	IN	O	14	VMOD	O
O	O	O	82	92	inhibition	inhibition	B-NP	NN	O	15	PMOD	O
O	O	O	93	95	of	of	B-PP	IN	O	16	NMOD	O
T3	B-Entity	B-Entity	96	103	nuclear	nuclear	B-NP	JJ	B-protein	22	NMOD	B-protein
T3	I-Entity	I-Entity	104	110	factor	factor	I-NP	NN	I-protein	22	NMOD	I-protein
T3	I-Entity	I-Entity	111	116	kappa	kappa	I-NP	NN	I-protein	22	NMOD	I-protein
T3	I-Entity	I-Entity	117	118	B	B	I-NP	NN	I-protein	22	NMOD	I-protein
O	O	O	119	126	binding	binding	I-NP	NN	O	17	PMOD	O
O	O	O	126	127	.	.	O	.	O	13	P	O

O	O	O	129	138	Oxidative	Oxidative	B-NP	JJ	O	2	NMOD	O
O	O	O	139	145	stress	stress	I-NP	NN	O	10	SUB	O
O	O	O	145	146	,	,	O	,	O	2	P	O
O	O	O	147	151	with	with	B-PP	IN	O	2	NMOD	O
O	O	O	152	160	reactive	reactive	B-NP	JJ	O	8	NMOD	O
O	O	O	161	167	oxygen	oxygen	I-NP	NN	O	8	NMOD	O
O	O	O	168	180	intermediate	intermediate	I-NP	JJ	O	8	NMOD	O
O	O	O	181	190	formation	formation	I-NP	NN	O	4	PMOD	O
O	O	O	190	191	,	,	O	,	O	2	P	O
O	O	O	192	195	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	196	205	represent	represent	I-VP	VB	O	10	VC	O
O	O	O	206	207	a	a	B-NP	DT	O	14	NMOD	O
O	O	O	208	214	common	common	I-NP	JJ	O	14	NMOD	O
O	O	O	215	224	mechanism	mechanism	I-NP	NN	O	11	OBJ	O
O	O	O	225	227	by	by	B-PP	IN	O	14	NMOD	O
O	O	O	228	233	which	which	B-NP	WDT	O	15	PMOD	O
O	O	O	234	239	liver	liver	B-NP	NN	O	18	NMOD	O
O	O	O	240	246	injury	injury	I-NP	NN	O	19	SUB	O
O	O	O	247	249	is	be	B-VP	VBZ	O	15	SBAR	O
O	O	O	250	257	induced	induce	I-VP	VBN	O	19	VC	O
O	O	O	258	260	by	by	B-PP	IN	O	20	VMOD	O
O	O	O	261	268	diverse	diverse	B-NP	JJ	O	23	NMOD	O
O	O	O	269	279	etiologies	etiology	I-NP	NNS	O	21	PMOD	O
O	O	O	279	280	.	.	O	.	O	10	P	O

O	O	O	281	290	Oxidative	Oxidative	B-NP	JJ	O	2	NMOD	O
O	O	O	291	297	stress	stress	I-NP	NN	O	3	SUB	O
O	O	O	298	306	enhances	enhance	B-VP	VBZ	O	22	VMOD	O
T4	B-Entity	B-Entity	307	314	nuclear	nuclear	B-NP	JJ	B-protein	7	NMOD	B-protein
T4	I-Entity	I-Entity	315	321	factor	factor	I-NP	NN	I-protein	7	NMOD	I-protein
T4	I-Entity	I-Entity	322	327	kappa	kappa	I-NP	NN	I-protein	7	NMOD	I-protein
T4	I-Entity	I-Entity	328	329	B	B	I-NP	NN	I-protein	14	NMOD	I-protein
O	O	O	330	331	(	(	O	(	O	13	DEP	O
T5	B-Entity	B-Entity	331	333	NF	NF	B-NP	NN	B-protein	12	NMOD	B-protein
T5	I-Entity	I-Entity	333	334	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T5	I-Entity	I-Entity	334	339	kappa	kappa	I-NP	NN	I-protein	12	NMOD	I-protein
T5	I-Entity	I-Entity	340	341	B	B	I-NP	NN	I-protein	13	DEP	I-protein
O	O	O	341	342	)	)	O	)	O	7	NMOD	O
O	O	O	343	351	activity	activity	B-NP	NN	O	3	OBJ	O
O	O	O	351	352	,	,	O	,	O	22	P	O
O	O	O	353	356	and	and	O	CC	O	22	VMOD	O
T6	B-Entity	B-Entity	357	359	NF	NF	B-NP	NN	B-protein	21	NMOD	B-protein
T6	I-Entity	I-Entity	359	360	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T6	I-Entity	I-Entity	360	365	kappa	kappa	I-NP	NN	I-protein	21	NMOD	I-protein
T6	I-Entity	I-Entity	366	367	B	B	I-NP	NN	I-protein	21	NMOD	I-protein
O	O	O	368	376	activity	activity	I-NP	NN	O	22	SUB	O
O	O	O	377	380	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	381	385	been	be	I-VP	VBN	O	22	VC	O
O	O	O	386	391	shown	show	I-VP	VBN	O	23	VC	O
O	O	O	392	394	to	to	I-VP	TO	O	26	VMOD	O
O	O	O	395	402	enhance	enhance	I-VP	VB	O	24	VMOD	O
O	O	O	403	406	the	the	B-NP	DT	O	28	NMOD	O
O	O	O	407	417	expression	expression	I-NP	NN	O	26	OBJ	O
O	O	O	418	420	of	of	B-PP	IN	O	28	NMOD	O
O	O	O	421	430	cytotoxic	cytotoxic	B-NP	JJ	B-protein	31	NMOD	B-protein
O	O	O	431	440	cytokines	cytokine	I-NP	NNS	I-protein	29	PMOD	I-protein
O	O	O	440	441	.	.	O	.	O	22	P	O

O	O	O	442	447	Acute	Acute	B-NP	JJ	O	3	NMOD	O
O	O	O	448	455	hepatic	hepatic	I-NP	JJ	O	3	NMOD	O
O	O	O	456	462	injury	injury	I-NP	NN	O	10	SUB	O
O	O	O	463	469	caused	cause	B-VP	VBN	O	3	NMOD	O
O	O	O	470	472	by	by	B-PP	IN	O	4	VMOD	O
O	O	O	473	481	reactive	reactive	B-NP	JJ	O	9	NMOD	O
O	O	O	482	488	oxygen	oxygen	I-NP	NN	O	9	NMOD	O
O	O	O	489	501	intermediate	intermediate	I-NP	JJ	O	9	NMOD	O
O	O	O	502	512	production	production	I-NP	NN	O	5	PMOD	O
O	O	O	513	516	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	517	524	induced	induce	I-VP	VBN	O	10	VC	O
O	O	O	525	527	by	by	B-PP	IN	O	11	VMOD	O
O	O	O	528	530	an	an	B-NP	DT	O	15	NMOD	O
O	O	O	531	546	intraperitoneal	intraperitoneal	I-NP	JJ	O	15	NMOD	O
O	O	O	547	556	injection	injection	I-NP	NN	O	12	PMOD	O
O	O	O	557	559	of	of	B-PP	IN	O	15	NMOD	O
O	O	O	560	564	CCl4	CCl4	B-NP	NN	B-protein	16	PMOD	B-protein
O	O	O	565	567	in	in	B-PP	IN	O	15	NMOD	O
O	O	O	568	572	mice	mouse	B-NP	NNS	O	18	PMOD	O
O	O	O	572	573	.	.	O	.	O	10	P	O

O	O	O	574	578	This	This	B-NP	DT	O	2	NMOD	O
O	O	O	579	585	injury	injury	I-NP	NN	O	3	SUB	O
O	O	O	586	589	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	590	603	significantly	significantly	I-VP	RB	O	3	VMOD	O
O	O	O	604	613	inhibited	inhibit	I-VP	VBN	O	3	VC	O
O	O	O	614	616	by	by	B-PP	IN	O	5	VMOD	O
O	O	O	617	628	intravenous	intravenous	B-NP	JJ	O	8	NMOD	O
O	O	O	629	641	pretreatment	pretreatment	I-NP	NN	O	6	PMOD	O
O	O	O	642	644	of	of	B-PP	IN	O	8	NMOD	O
O	O	O	645	648	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	649	653	mice	mouse	I-NP	NNS	O	9	PMOD	O
O	O	O	654	658	with	with	B-PP	IN	O	8	NMOD	O
O	O	O	659	660	a	a	B-NP	DT	O	17	NMOD	O
O	O	O	661	666	water	water	I-NP	NN	O	17	NMOD	O
O	O	O	666	667	-	-	B-NP	HYPH	O	17	NMOD	O
O	O	O	667	674	soluble	soluble	I-NP	JJ	O	17	NMOD	O
O	O	O	675	683	emulsion	emulsion	I-NP	NN	O	12	PMOD	O
O	O	O	684	686	of	of	B-PP	IN	O	17	NMOD	O
O	O	O	687	692	alpha	alpha	B-NP	SYM	O	21	NMOD	O
O	O	O	692	693	-	-	B-VP	HYPH	O	21	NMOD	O
O	O	O	693	703	tocopherol	tocopherol	B-NP	NN	O	18	PMOD	O
O	O	O	703	704	.	.	O	.	O	3	P	O

O	O	O	705	710	Alpha	Alpha	B-NP	NN	B-protein	4	NMOD	B-protein
O	O	O	710	711	-	-	I-NP	HYPH	O	4	NMOD	O
O	O	O	711	721	tocopherol	tocopherol	I-NP	NN	O	4	NMOD	O
O	O	O	722	731	treatment	treatment	I-NP	NN	O	12	SUB	O
O	O	O	732	734	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	735	738	the	the	B-NP	DT	O	7	NMOD	O
O	O	O	739	743	mice	mouse	I-NP	NNS	O	5	PMOD	O
O	O	O	744	749	given	give	B-VP	VBN	O	7	NMOD	O
O	O	O	750	753	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	754	758	CCl4	CCl4	I-NP	NN	O	8	OBJ	O
O	O	O	759	763	also	also	B-ADVP	RB	O	12	VMOD	O
O	O	O	764	771	reduced	reduce	B-VP	VBD	O	0	ROOT	O
O	O	O	772	775	the	the	B-NP	DT	O	17	NMOD	O
T7	B-Entity	B-Entity	776	778	NF	NF	I-NP	NN	B-protein	17	NMOD	B-protein
T7	I-Entity	I-Entity	778	779	-	-	B-NP	HYPH	I-protein	17	P	I-protein
T7	I-Entity	I-Entity	779	784	kappa	kappa	I-NP	NN	I-protein	17	NMOD	I-protein
T7	I-Entity	I-Entity	785	786	B	B	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	O	787	794	binding	bind	B-VP	VBG	O	12	OBJ	O
O	O	O	795	797	to	to	B-PP	TO	O	12	VMOD	O
O	O	O	798	804	levels	level	B-NP	NNS	O	19	PMOD	O
O	O	O	805	816	approaching	approach	B-VP	VBG	O	20	NMOD	O
O	O	O	817	822	those	those	B-NP	DT	O	21	OBJ	O
O	O	O	823	828	found	find	B-VP	VBN	O	22	NMOD	O
O	O	O	829	831	in	in	B-PP	IN	O	23	VMOD	O
O	O	O	832	838	normal	normal	B-NP	JJ	O	26	NMOD	O
O	O	O	839	843	mice	mouse	I-NP	NNS	O	24	PMOD	O
O	O	O	843	844	.	.	O	.	O	12	P	O

O	O	O	845	847	In	In	B-NP	FW	O	2	AMOD	O
O	O	O	848	853	vitro	vitro	I-NP	FW	O	3	NMOD	O
O	O	O	854	863	treatment	treatment	I-NP	NN	O	13	SUB	O
O	O	O	864	866	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	867	868	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	869	877	monocyte	monocyte	I-NP	NN	B-cell_type	10	NMOD	B-cell_type
O	O	O	877	878	/	/	O	SYM	O	10	P	O
O	O	O	878	888	macrophage	macrophage	B-NP	NN	B-cell_line	10	NMOD	B-cell_line
O	O	O	889	893	cell	cell	I-NP	NN	I-cell_line	10	NMOD	I-cell_line
O	O	O	894	898	line	line	I-NP	NN	I-cell_line	4	PMOD	I-cell_line
O	O	O	899	903	with	with	B-PP	IN	O	3	NMOD	O
O	O	O	904	908	CCl4	CCl4	B-NP	NN	O	11	PMOD	O
O	O	O	909	912	led	lead	B-VP	VBD	O	0	ROOT	O
O	O	O	913	915	to	to	B-PP	TO	O	13	VMOD	O
O	O	O	916	924	enhanced	enhance	B-NP	VBN	O	20	NMOD	O
T8	B-Entity	B-Entity	925	927	NF	NF	I-NP	NN	B-protein	20	NMOD	B-protein
T8	I-Entity	I-Entity	927	928	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T8	I-Entity	I-Entity	928	933	kappa	kappa	I-NP	NN	I-protein	20	NMOD	I-protein
T8	I-Entity	I-Entity	934	935	B	B	I-NP	NN	I-protein	20	NMOD	I-protein
O	O	O	936	943	binding	binding	I-NP	NN	O	23	NMOD	O
O	O	O	944	947	and	and	O	CC	O	23	NMOD	O
O	O	O	948	950	an	an	B-NP	DT	O	23	NMOD	O
O	O	O	951	959	increase	increase	I-NP	NN	O	14	PMOD	O
O	O	O	960	962	in	in	B-PP	IN	O	23	NMOD	O
T1	B-Protein	B-Protein	963	968	tumor	tumor	B-NP	NN	B-protein	29	NMOD	B-protein
T1	I-Protein	I-Protein	969	977	necrosis	necrosis	I-NP	NN	I-protein	29	NMOD	I-protein
T1	I-Protein	I-Protein	978	984	factor	factor	I-NP	NN	I-protein	29	NMOD	I-protein
T1	I-Protein	I-Protein	984	985	-	-	O	HYPH	I-protein	29	P	I-protein
T1	I-Protein	I-Protein	985	990	alpha	alpha	B-NP	SYM	I-protein	35	NMOD	I-protein
O	O	O	991	992	(	(	O	(	O	34	DEP	O
T2	B-Protein	B-Protein	992	995	TNF	TNF	B-NP	NN	B-protein	33	NMOD	B-protein
T2	I-Protein	I-Protein	995	996	-	-	O	HYPH	O	33	P	O
T2	I-Protein	I-Protein	996	1001	alpha	alpha	O	SYM	O	34	DEP	O
O	O	O	1001	1002	)	)	O	)	O	29	NMOD	O
O	O	O	1003	1012	messenger	messenger	B-NP	NN	O	37	NMOD	O
O	O	O	1013	1016	RNA	RNA	I-NP	NN	O	37	NMOD	O
O	O	O	1017	1023	levels	level	I-NP	NNS	O	24	PMOD	O
O	O	O	1023	1024	.	.	O	.	O	13	P	O

O	O	O	1025	1030	Liver	Liver	B-NP	NN	O	2	NMOD	O
O	O	O	1031	1040	specimens	specimen	I-NP	NNS	O	10	SUB	O
O	O	O	1041	1046	taken	take	B-VP	VBN	O	2	NMOD	O
O	O	O	1047	1051	from	from	B-PP	IN	O	3	VMOD	O
O	O	O	1052	1060	patients	patient	B-NP	NNS	O	4	PMOD	O
O	O	O	1061	1065	with	with	B-PP	IN	O	5	NMOD	O
O	O	O	1066	1071	acute	acute	B-NP	JJ	O	8	AMOD	O
O	O	O	1072	1081	fulminant	fulminant	I-NP	JJ	O	9	NMOD	O
O	O	O	1082	1091	hepatitis	hepatitis	I-NP	NN	O	6	PMOD	O
O	O	O	1092	1095	had	have	B-VP	VBD	O	0	ROOT	O
O	O	O	1096	1104	markedly	markedly	I-VP	RB	O	10	VMOD	O
O	O	O	1105	1114	increased	increase	I-VP	VBN	O	10	VC	O
T9	B-Entity	B-Entity	1115	1117	NF	NF	B-NP	NN	B-protein	18	NMOD	B-protein
T9	I-Entity	I-Entity	1117	1118	-	-	B-NP	HYPH	I-protein	18	NMOD	I-protein
T9	I-Entity	I-Entity	1118	1123	kappa	kappa	I-NP	NN	I-protein	18	NMOD	I-protein
T9	I-Entity	I-Entity	1124	1125	B	B	I-NP	NN	I-protein	18	NMOD	I-protein
O	O	O	1126	1133	binding	binding	I-NP	NN	O	18	NMOD	O
O	O	O	1134	1142	activity	activity	I-NP	NN	O	12	OBJ	O
O	O	O	1143	1145	in	in	B-PP	IN	O	12	VMOD	O
O	O	O	1146	1156	comparison	comparison	B-NP	NN	O	19	PMOD	O
O	O	O	1157	1161	with	with	B-PP	IN	O	20	NMOD	O
O	O	O	1162	1165	the	the	B-NP	DT	O	23	NMOD	O
O	O	O	1166	1173	binding	binding	I-NP	NN	O	21	PMOD	O
O	O	O	1174	1176	of	of	B-PP	IN	O	23	NMOD	O
O	O	O	1177	1183	normal	normal	B-NP	JJ	O	26	NMOD	O
O	O	O	1184	1190	livers	liver	I-NP	NNS	O	24	PMOD	O
O	O	O	1190	1191	.	.	O	.	O	10	P	O

O	O	O	1192	1197	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1198	1202	data	datum	I-NP	NNS	O	3	SUB	O
O	O	O	1203	1214	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	O	1215	1219	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1220	1230	abolishing	abolish	B-VP	VBG	O	20	SUB	O
O	O	O	1231	1236	acute	acute	B-NP	JJ	O	8	NMOD	O
O	O	O	1237	1244	hepatic	hepatic	I-NP	JJ	O	8	NMOD	O
O	O	O	1245	1251	injury	injury	I-NP	NN	O	5	OBJ	O
O	O	O	1252	1256	with	with	B-PP	IN	O	5	VMOD	O
O	O	O	1257	1262	alpha	alpha	B-NP	SYM	O	17	NMOD	O
O	O	O	1262	1263	-	-	O	HYPH	O	17	NMOD	O
O	O	O	1263	1273	tocopherol	tocopherol	B-NP	NN	O	17	NMOD	O
O	O	O	1273	1274	,	,	O	,	O	17	P	O
O	O	O	1275	1276	a	a	B-NP	DT	O	17	NMOD	O
O	O	O	1277	1281	free	free	I-NP	JJ	O	17	NMOD	O
O	O	O	1282	1289	radical	radical	I-NP	NN	O	17	NMOD	O
O	O	O	1290	1299	scavenger	scavenger	I-NP	NN	O	9	PMOD	O
O	O	O	1299	1300	,	,	O	,	O	5	P	O
O	O	O	1301	1305	also	also	B-ADVP	RB	O	20	VMOD	O
O	O	O	1306	1316	eliminated	eliminate	B-VP	VBD	O	4	SBAR	O
O	O	O	1317	1326	increased	increase	B-NP	VBN	O	26	NMOD	O
T10	B-Entity	B-Entity	1327	1329	NF	NF	I-NP	NN	B-protein	26	NMOD	B-protein
T10	I-Entity	I-Entity	1329	1330	-	-	B-NP	HYPH	I-protein	26	NMOD	I-protein
T10	I-Entity	I-Entity	1330	1335	kappa	kappa	I-NP	NN	I-protein	26	NMOD	I-protein
T10	I-Entity	I-Entity	1336	1337	B	B	I-NP	NN	I-protein	26	NMOD	I-protein
O	O	O	1338	1345	binding	binding	I-NP	NN	O	20	OBJ	O
O	O	O	1345	1346	.	.	O	.	O	3	P	O

O	O	O	1347	1349	It	It	B-NP	PRP	O	2	SUB	O
O	O	O	1350	1352	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1353	1361	tempting	tempt	I-VP	VBG	O	2	PRD	O
O	O	O	1362	1364	to	to	I-VP	TO	O	5	VMOD	O
O	O	O	1365	1374	speculate	speculate	I-VP	VB	O	2	VMOD	O
O	O	O	1375	1379	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	O	1380	1388	enhanced	enhance	B-NP	VBN	O	12	NMOD	O
T11	B-Entity	B-Entity	1389	1391	NF	NF	I-NP	NN	B-protein	12	NMOD	B-protein
T11	I-Entity	I-Entity	1391	1392	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T11	I-Entity	I-Entity	1392	1397	kappa	kappa	I-NP	NN	I-protein	12	NMOD	I-protein
T11	I-Entity	I-Entity	1398	1399	B	B	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	O	1400	1410	expression	expression	I-NP	NN	O	21	SUB	O
O	O	O	1411	1417	caused	cause	B-VP	VBN	O	12	NMOD	O
O	O	O	1418	1420	by	by	B-PP	IN	O	13	VMOD	O
O	O	O	1421	1425	free	free	B-NP	JJ	O	20	NMOD	O
O	O	O	1426	1433	radical	radical	I-NP	NN	O	20	NMOD	O
O	O	O	1434	1444	production	production	I-NP	NN	O	20	NMOD	O
O	O	O	1444	1445	/	/	B-NP	SYM	O	20	P	O
O	O	O	1445	1454	oxidative	oxidative	I-NP	JJ	O	20	NMOD	O
O	O	O	1455	1461	stress	stress	I-NP	NN	O	14	PMOD	O
O	O	O	1462	1465	may	may	B-VP	MD	O	6	SBAR	O
O	O	O	1466	1474	modulate	modulate	I-VP	VB	O	21	VC	O
O	O	O	1475	1480	liver	liver	B-NP	NN	O	24	NMOD	O
O	O	O	1481	1487	injury	injury	I-NP	NN	O	22	OBJ	O
O	O	O	1487	1488	,	,	O	,	O	22	P	O
O	O	O	1489	1496	perhaps	perhaps	B-ADVP	RB	O	27	PMOD	O
O	O	O	1497	1504	through	through	B-PP	IN	O	22	VMOD	O
O	O	O	1505	1507	an	an	B-NP	DT	O	29	NMOD	O
O	O	O	1508	1514	effect	effect	I-NP	NN	O	27	PMOD	O
O	O	O	1515	1517	on	on	B-PP	IN	O	29	NMOD	O
O	O	O	1518	1527	cytotoxic	cytotoxic	B-NP	JJ	B-protein	33	NMOD	B-protein
O	O	O	1528	1536	cytokine	cytokine	I-NP	NN	I-protein	33	NMOD	I-protein
O	O	O	1537	1546	synthesis	synthesis	I-NP	NN	O	30	PMOD	O
O	O	O	1546	1547	.	.	O	.	O	2	P	O
